Abstract Number: 0137 • ACR Convergence 2022
Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
Background/Purpose: Farber disease is frequently misdiagnosed as polyarticular juvenile idiopathic arthritis or seronegative rheumatoid arthritis which leads to a delay in diagnosis for many patients.…Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…Abstract Number: 0261 • ACR Convergence 2022
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…Abstract Number: 0278 • ACR Convergence 2022
The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
Background/Purpose: Reporting of treatment-emergent adverse events (TEAEs) in RA clinical trials can be summarized as exposure-adjusted incidence rates (EAIRs) or exposure-adjusted event rates (EAERs). Censored…Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…Abstract Number: 0593 • ACR Convergence 2022
A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation
Background/Purpose: IL-40 is a newly described cytokine related to malignant transformation and immune system function. In our previous study, we showed that IL-40 is elevated…Abstract Number: 0610 • ACR Convergence 2022
Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation
Background/Purpose: Synovial lining fibroblasts secrete factors into the joint cavity that promote joint lubrication1. In inflammatory arthritis, sublining fibroblasts undergo marked expansion while lining fibroblasts…Abstract Number: 0627 • ACR Convergence 2022
Spatial Transcriptomic Analysis Reveals Vascular Zonation of Myofibroblasts in Rheumatoid Arthritis Synovium
Background/Purpose: Many rheumatoid arthritis (RA) patients do not achieve sustained remission despite multiple lines of therapy. Recent studies have linked the expansion of synovial fibroblasts…Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…Abstract Number: 0899 • ACR Convergence 2022
Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis
Background/Purpose: Multiple questionnaires and objective assessment tools have been developed to determine functional compromise in Rheumatoid Arthritis (RA). One of the most used tools to…Abstract Number: 0915 • ACR Convergence 2022
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
Background/Purpose: Analyses of methotrexate polyglutamates (MTX-PGs) in red blood cells (RBCs) has been employed as tool for personalized therapy approach for RA patients during MTX…Abstract Number: 0931 • ACR Convergence 2022
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Background/Purpose: Active rheumatoid arthritis (RA) despite methotrexate (MTX) monotherapy is seen in about 40-50% of patients1. The current ACR guidelines recommend adding a biologic or…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 188
- Next Page »